Market Cap 546.08M
Revenue (ttm) 3.93M
Net Income (ttm) -126.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,212.21%
Debt to Equity Ratio 0.00
Volume 1,125,958
Avg Vol 1,989,840
Day's Range N/A - N/A
Shares Out 295.18M
Stochastic %K 58%
Beta 1.78
Analysts Sell
Price Target $6.00

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
MALO_MY_BOY
MALO_MY_BOY Jul. 17 at 3:50 PM
0 · Reply
Jmkconcrete1
Jmkconcrete1 Jul. 16 at 9:36 PM
$PGEN it’s all about who you know,he knows the game ,fda will 100% pass it
0 · Reply
Wacousta
Wacousta Jul. 16 at 9:17 PM
$PGEN Confirmatory study now in progress will be the pivotal to the final outcome. If the new data mirrors the existing data or better; chances of approval are much higher. If not, all sorts of scenarios come into play; and the need for new money. As always a dreaded Black Swan event is also possible. I think Dr. Sabzevari has this; I’ve been wrong before though.
1 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Jul. 16 at 7:09 PM
$PGEN Very strong resistance at $2. We were essentially trading at this level when the BLA submission was official. After that initial spike above $2 the stock is back where it’s been. We are 4-5 weeks away from an FDA decision that can change everything, but based on the current trading it appears the market is not optimistic about an FDA approval as a potential likely outcome. I’m surprised more traders are not willing to roll the dice on positive news. I’m praying for good news but the FDA has knifed me in the back so many times I think I know deep down inside there is pain in my future.
1 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 4:09 PM
Sell $CAPR Buy $PGEN
0 · Reply
rubraquercus
rubraquercus Jul. 16 at 12:54 PM
$PGEN I would not cross the street to piss on kirkiefuk if he was on fire
1 · Reply
Ibragrs
Ibragrs Jul. 16 at 9:14 AM
$PGEN The sleeper play is waking up. FDA decision incoming Aug 27. 👀 First-ever therapeutic for RRP, fast-track approval, commercial-ready DAY 1. Est. 75–85% approval chance, biotech insiders loading. Tiny float + strong data = 🚀 potential. Chart coiled hard — breakout above 2.00 incoming. Holding tight from 1.87 — target $4–5 short term if FDA hits. 💰💥 Let’s go apes. Diamond hands. 🧬🔥 #Biotech #PDUFA #FDA
1 · Reply
updownsides
updownsides Jul. 16 at 7:40 AM
0 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 2:10 AM
0 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 1:29 AM
SELL $CAPR BUY $PGEN PGEN has a PDUFA date of August 27, 2025, with a strong possibility for gene therapy approval for treatment of recurrent respiratory papillomatosis (RRP).
0 · Reply
Latest News on PGEN
Precigen: August Is Pivotal For This Biotech Innovator

Jul 7, 2025, 5:58 PM EDT - 9 days ago

Precigen: August Is Pivotal For This Biotech Innovator


Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:47 PM EDT - 4 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript


Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 8 months ago

Precigen to Participate in the Stifel 2024 Healthcare Conference


Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript


Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA


Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript


Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 19, 2024, 7:39 PM EST - 1 year ago

Precigen: RRP Targeting With AdenoVerse Technology Platform


Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 3:03 PM EDT - 2 years ago

Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript


MALO_MY_BOY
MALO_MY_BOY Jul. 17 at 3:50 PM
0 · Reply
Jmkconcrete1
Jmkconcrete1 Jul. 16 at 9:36 PM
$PGEN it’s all about who you know,he knows the game ,fda will 100% pass it
0 · Reply
Wacousta
Wacousta Jul. 16 at 9:17 PM
$PGEN Confirmatory study now in progress will be the pivotal to the final outcome. If the new data mirrors the existing data or better; chances of approval are much higher. If not, all sorts of scenarios come into play; and the need for new money. As always a dreaded Black Swan event is also possible. I think Dr. Sabzevari has this; I’ve been wrong before though.
1 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Jul. 16 at 7:09 PM
$PGEN Very strong resistance at $2. We were essentially trading at this level when the BLA submission was official. After that initial spike above $2 the stock is back where it’s been. We are 4-5 weeks away from an FDA decision that can change everything, but based on the current trading it appears the market is not optimistic about an FDA approval as a potential likely outcome. I’m surprised more traders are not willing to roll the dice on positive news. I’m praying for good news but the FDA has knifed me in the back so many times I think I know deep down inside there is pain in my future.
1 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 4:09 PM
Sell $CAPR Buy $PGEN
0 · Reply
rubraquercus
rubraquercus Jul. 16 at 12:54 PM
$PGEN I would not cross the street to piss on kirkiefuk if he was on fire
1 · Reply
Ibragrs
Ibragrs Jul. 16 at 9:14 AM
$PGEN The sleeper play is waking up. FDA decision incoming Aug 27. 👀 First-ever therapeutic for RRP, fast-track approval, commercial-ready DAY 1. Est. 75–85% approval chance, biotech insiders loading. Tiny float + strong data = 🚀 potential. Chart coiled hard — breakout above 2.00 incoming. Holding tight from 1.87 — target $4–5 short term if FDA hits. 💰💥 Let’s go apes. Diamond hands. 🧬🔥 #Biotech #PDUFA #FDA
1 · Reply
updownsides
updownsides Jul. 16 at 7:40 AM
0 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 2:10 AM
0 · Reply
MALO_MY_BOY
MALO_MY_BOY Jul. 16 at 1:29 AM
SELL $CAPR BUY $PGEN PGEN has a PDUFA date of August 27, 2025, with a strong possibility for gene therapy approval for treatment of recurrent respiratory papillomatosis (RRP).
0 · Reply
iBio_GlaisterPIT
iBio_GlaisterPIT Jul. 15 at 6:41 PM
$PGEN Is PRGN-3006’s phase I still set to complete 08-01-25? Why is it not talked about?
1 · Reply
iBio_GlaisterPIT
iBio_GlaisterPIT Jul. 15 at 6:29 PM
$PGEN I don’t know about others, but I wouldn’t expect much from earnings next month. The FDA review expected end of August is the catalyst I’m looking forward to.
0 · Reply
Wacousta
Wacousta Jul. 15 at 6:15 PM
$PGEN FYI https://datadashboard.fda.gov/oii/firmprofile.htm?FEIi=3014429654&/identity/3014429654
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Jul. 15 at 2:57 PM
$PGEN Can’t stay above $2. So annoying.
1 · Reply
updownsides
updownsides Jul. 15 at 4:57 AM
$PGEN Just another day before next month's approval. Bring the volume!
0 · Reply
LifeisaMeme
LifeisaMeme Jul. 15 at 2:44 AM
$PGEN REMIND EM LET EM KNOWWWWWWW OMG LMAO
1 · Reply
M22
M22 Jul. 14 at 6:38 PM
$PGEN https://youtu.be/U9z5BsvtkyM?si=W61QLTuI1PzdF_iv
0 · Reply
M22
M22 Jul. 14 at 6:34 PM
$PGEN https://www.ainvest.com/news/precigen-prgn-2012-rare-disease-breakthrough-awaits-fda-decision-august-2025-2507/
0 · Reply
M22
M22 Jul. 14 at 6:33 PM
$PGEN https://www.aaii.com/investingideas/article/313414-why-precigen-inc8217s-pgen-stock-is-up-765
0 · Reply
BentleyT99
BentleyT99 Jul. 14 at 6:06 PM
3 · Reply
forgottenchuck
forgottenchuck Jul. 14 at 6:04 PM
$PGEN going alot higher folks especially when we hit august
0 · Reply
BentleyT99
BentleyT99 Jul. 14 at 6:03 PM
0 · Reply